WAVEMAN · COMPANY

ABSI · Absci Corp

LIVE

TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475

← ALL COMPANIES

ABSI

Name: Absci Corp (ABSI) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Absci Corp

PHARMA & BIOTECH · SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH · CIK 0001672688

CLUSTER · 3 INSIDERSC-SUITE BUYING · 1☆ WATCH

INSIDER NET · 180D

$578.6K

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

126

13F, latest reported quarter

REVENUE GROWTH

-38.2%

XBRL, annual

NET MARGIN

-4113.7%

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net +$578.6K over 180 days

+$148.9K over 90 days

more than 86% of Pharma & Biotech

CONGRESS

no member of Congress has reported trading it

FUNDS

126 funds added or opened last quarter

more than 74% of Pharma & Biotech

REVENUE

-38.2% year over year

below 80% of Pharma & Biotech

MARGIN

-4113.7% net margin

below 97% of Pharma & Biotech

BUYBACKS

no share repurchases reported

SHORT

21.7% of shares outstanding short · 11.7 days to cover · settled 2026-07-31

more than 97% of Pharma & Biotech

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

3 insiders independently bought a net $578.6K — no planned sales are queued against it.

126 funds added or opened positions in the latest 13F quarter, of 199 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +276.1%

+276.1%12M

INSIDER BUYINSIDER SELL

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

3 insiders reported buying shares.

The record shows a net $578.6K bought by insiders over 180 days, 126 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Absci Corp insiders bought a net $578.6K of stock across 31 Form 4 purchases and sales, with 3 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-04.

INSIDER

FILED

VALUE

Szela Mary T

Director

BUY

2026-06-30

12,900.0

$148.9K

Pangalos Menelas N

Director

BUY

2026-05-13

37,453.0

$200.7K

Busch Andreas

Chief Innovation Officer

BUY

2026-03-12

100,000.0

$229.0K

Pangalos Menelas N

Director

BUY

2026-02-27

75,095.0

$205.8K

McClain Sean

Chief Executive Officer

SELL

2026-02-02

26,761.0

$80.0K

31 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 26 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

FMR LLC

25,410,048.0 sh

$294.5M

ARK Investment Management LLC

12,925,271.0 sh

$149.8M

BlackRock, Inc.

12,175,302.0 sh

$141.1M

STATE STREET CORP

8,097,308.0 sh

$93.8M

AMERIPRISE FINANCIAL INC

6,991,763.0 sh

$81.0M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

ARK Genomic Revolution ETF

$59.1M POSITION · AS OF 2026-04-30

4.8%

ALGER SMALL CAP GROWTH FUND

$3.3M POSITION · AS OF 2026-04-30

1.7%

ALGER SMALL CAP GROWTH INSTITUTIONAL FUND

$927.8K POSITION · AS OF 2026-04-30

1.3%

Alger Small Cap Growth Portfolio

$1.0M POSITION · AS OF 2026-03-31

0.8%

Columbia Acorn Fund

$7.7M POSITION · AS OF 2026-03-31

0.3%

Columbia Variable Portfolio - Acorn Fund

$1.5M POSITION · AS OF 2026-03-31

0.3%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$2.8M	$4.5M	$5.7M	$4.5M
OPERATING INCOME	$-120.3M	$-108.9M	$-115.5M	$-106.8M
NET INCOME	$-115.2M	$-103.1M	$-110.6M	$-104.9M
EPS (DILUTED)	-0.84	-0.94	-1.20	-1.15
OPERATING CASH FLOW	$-92.9M	$-72.4M	$-64.6M	$-81.3M
CASH	$20.0M	$41.2M	$72.4M	$60.0M
LONG-TERM DEBT	—	$4.0M	$7.9M	$10.9M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-04 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE